Tim Lugo
Stock Analyst at William Blair
(0.57)
# 3,815
Out of 4,734 analysts
29
Total ratings
35.29%
Success rate
-22.02%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tim Lugo
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EYEN Eyenovia | Downgrades: Market Perform | n/a | $0.06 | - | 2 | Nov 15, 2024 | |
| BMRN BioMarin Pharmaceutical | Downgrades: Market Perform | n/a | $61.53 | - | 3 | Oct 30, 2024 | |
| RVNC Revance Therapeutics | Downgrades: Market Perform | n/a | $3.68 | - | 1 | Aug 12, 2024 | |
| APLT Applied Therapeutics | Initiates: Outperform | n/a | $0.65 | - | 1 | Jul 31, 2024 | |
| LENZ LENZ Therapeutics | Initiates: Outperform | n/a | $22.50 | - | 1 | Apr 15, 2024 | |
| SLDB Solid Biosciences | Initiates: Outperform | $40 | $3.27 | +1,123.24% | 1 | Mar 28, 2024 | |
| ZVRA Zevra Therapeutics | Initiates: Outperform | n/a | $8.05 | - | 1 | Mar 12, 2024 | |
| ABBV AbbVie | Upgrades: Outperform | n/a | $171.56 | - | 2 | Jan 29, 2024 | |
| ALLK Allakos | Upgrades: Outperform | n/a | $0.86 | - | 3 | Dec 18, 2023 | |
| ACRS Aclaris Therapeutics | Downgrades: Market Perform | n/a | $2.57 | - | 1 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $18.37 | - | 1 | Sep 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $12.57 | - | 2 | Sep 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.92 | - | 3 | Jul 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $62 | $7.08 | +775.71% | 1 | Jun 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $3.37 | - | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $38.52 | - | 1 | Jan 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.19 | - | 2 | Sep 22, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $0.74 | - | 1 | May 30, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $46 | $37.59 | +22.37% | 1 | May 30, 2017 |
Eyenovia
Nov 15, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $0.06
Upside: -
BioMarin Pharmaceutical
Oct 30, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $61.53
Upside: -
Revance Therapeutics
Aug 12, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $3.68
Upside: -
Applied Therapeutics
Jul 31, 2024
Initiates: Outperform
Price Target: n/a
Current: $0.65
Upside: -
LENZ Therapeutics
Apr 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $22.50
Upside: -
Solid Biosciences
Mar 28, 2024
Initiates: Outperform
Price Target: $40
Current: $3.27
Upside: +1,123.24%
Zevra Therapeutics
Mar 12, 2024
Initiates: Outperform
Price Target: n/a
Current: $8.05
Upside: -
AbbVie
Jan 29, 2024
Upgrades: Outperform
Price Target: n/a
Current: $171.56
Upside: -
Allakos
Dec 18, 2023
Upgrades: Outperform
Price Target: n/a
Current: $0.86
Upside: -
Aclaris Therapeutics
Nov 13, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $2.57
Upside: -
Sep 21, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $18.37
Upside: -
Sep 20, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $12.57
Upside: -
Jul 22, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $2.92
Upside: -
Jun 16, 2021
Downgrades: Market Perform
Price Target: $62
Current: $7.08
Upside: +775.71%
Nov 24, 2020
Initiates: Outperform
Price Target: n/a
Current: $3.37
Upside: -
Jan 8, 2020
Initiates: Outperform
Price Target: n/a
Current: $38.52
Upside: -
Sep 22, 2017
Upgrades: Outperform
Price Target: n/a
Current: $1.19
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: n/a
Current: $0.74
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: $46
Current: $37.59
Upside: +22.37%